Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle.

OBJECTIVE The objective of this study is to assess lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with pancreatic ductal adenocarcinoma. METHODS Magnetic resonance imaging was performed in 13 patients with known or high index of suspicion of pancreatic cancer and who were scheduled for surgical resection. Protocols included T2*-weighted imaging before and after administration of Ferumoxytol (Feraheme) for the evaluation of lymph node involvement. Eleven of the 13 patients underwent a Whipple procedure and lymph node dissection. Nodes that lacked contrast uptake were deemed malignant, and those that demonstrated homogeneous uptake were deemed benign. RESULTS A total of 264 lymph nodes were resection, of which 17 were malignant. The sensitivity and specificity of LNMRI was 76.5% and 98.4% at a nodal level and 83.3% and 80% at a patient level. CONCLUSION LNMRI demonstrated high sensitivity and specificity in patients with pancreatic ductal adenocarcinoma.

[1]  V. Magnotta,et al.  Imaging aspirin effect on macrophages in the wall of human cerebral aneurysms using ferumoxytol-enhanced MRI: preliminary results. , 2013, Journal of neuroradiology. Journal de neuroradiologie.

[2]  Kazuhide Yamamoto,et al.  Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer: Impact on Diagnosis, Staging, Evaluation of Treatment Response, and Detection of Recurrence , 2013, Pancreas.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  M. Gönen,et al.  Hepatic Arterial Nodal Metastases in Pancreatic Cancer: Is This the Node of Importance? , 2013, Journal of Gastrointestinal Surgery.

[5]  H. Winn,et al.  Abstract 107: Early Change in Ferumoxytol-Enhanced Magnetic Resonance Imaging Signal Suggests Unstable Human Cerebral Aneurysm. A Pilot Study , 2013 .

[6]  M. Tempero,et al.  Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer , 2012, Cancer journal.

[7]  V. Velculescu,et al.  Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing , 2012, Clinical Cancer Research.

[8]  S. Yachida Novel therapeutic approaches in pancreatic cancer based on genomic alterations. , 2012, Current pharmaceutical design.

[9]  Hedvig Hricak,et al.  Molecular imaging for personalized cancer care , 2012, Molecular oncology.

[10]  J. Norton,et al.  Intensity-modulated radiotherapy for pancreatic adenocarcinoma. , 2012, International journal of radiation oncology, biology, physics.

[11]  Hong-Xia Wang,et al.  Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[12]  K. Lillemoe,et al.  N0/N1, PNL, or LNR? The Effect of Lymph Node Number on Accurate Survival Prediction in Pancreatic Ductal Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[13]  Steven F Petit,et al.  Increased organ sparing using shape-based treatment plan optimization for intensity modulated radiation therapy of pancreatic adenocarcinoma. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  G. Narayanan,et al.  A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma , 2012, BMC Cancer.

[15]  Jongphil Kim,et al.  Neoadjuvant GTX Chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancer , 2011, Journal of surgical oncology.

[16]  E. Furth,et al.  Analysis of the Human Pancreatic Stellate Cell Secreted Proteome , 2011, Pancreas.

[17]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[18]  H. Ohge,et al.  Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. , 2010, Journal of the American College of Surgeons.

[19]  H. Imai,et al.  Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer , 2010, International Journal of Clinical Oncology.

[20]  Irina Rinta-Kiikka,et al.  F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic Cancer , 2009 .

[21]  A. Muratore,et al.  Prognostic Significance of Lymph Node Metastases in Pancreatic Head Cancer Treated with Extended Lymphadenectomy: Not Just a Matter of Numbers , 2009, Annals of Surgical Oncology.

[22]  T. Keck,et al.  The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer , 2009, Journal of Gastrointestinal Surgery.

[23]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[24]  R. Weissleder,et al.  Utility of a new bolus-injectable nanoparticle for clinical cancer staging. , 2007, Neoplasia.

[25]  M. Choti,et al.  Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis , 2007, Annals of Surgical Oncology.

[26]  M. Gönen,et al.  Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.

[27]  M. Choti,et al.  Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. , 2007, Surgery.

[28]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[29]  R. Weissleder,et al.  Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. , 2006, AJR. American journal of roentgenology.

[30]  T. Helbich,et al.  Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. , 2006, Radiology.

[31]  David D. Smith,et al.  Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database , 2006, Annals of Surgical Oncology.

[32]  I. Narabayashi,et al.  Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10 , 2006, Gastric Cancer.

[33]  S. Maithel,et al.  Impact of Regional Lymph Node Evaluation in Staging Patients With Periampullary Tumors , 2006, Annals of Surgical Oncology.

[34]  M. Harisinghani,et al.  Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Imamura,et al.  Prognostic Implication of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer , 2005, World Journal of Surgery.

[36]  Mukesh G Harisinghani,et al.  Current concepts in lymph node imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[38]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.